Intervention Thresholds for Denosumab in the UK Using a FRAX®-based Cost-effectiveness Analysis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2012 Dec 11

PMID 23224141

Citations 21

Authors

O Strom

B Jonsson

J A Kanis

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The objective was to undertake a health economic analysis of denosumab for the treatment of osteoporosis in women from the UK, using the FRAX® tool. Denosumab was cost-effective in women with a risk of major osteoporotic fracture meeting or exceeding approximately 20% who are unable to take, comply with or tolerate generic alendronate.

Introduction: Denosumab is a novel biologic agent developed for the treatment of osteoporosis, which has been shown to reduce the risk of fractures in a phase-III trial. The objective of the present study was to undertake a health economic analysis of denosumab in women from the UK. Ten-year probabilities of a major osteoporotic fracture at which denosumab is a cost-effective alternative to no treatment, generic alendronate, risedronate and strontium ranelate were estimated.

Methods: A previously published Markov model was adapted to incorporate fracture and mortality risk assessments based on absolute fracture probability, as estimated by FRAX®. The model included treatment persistence and residual effect after discontinuation.

Results: At a willingness-to-pay (WTP) of £30,000 per quality-adjusted life year and a 10-year fracture probability equivalent to a woman with a prior fragility fracture, denosumab was cost-effective compared to no treatment from the age of 70 years. At the same WTP, denosumab was-irrespective of age-cost-effective compared to no treatment at a major osteoporotic fracture probability of approximately 20%. Denosumab was estimated to cost-effectively replace strontium, risedronate and generic alendronate at 10-year probabilities exceeding 11, 19 and 32%, respectively.

Conclusion: FRAX® facilitates the estimation of cost-effectiveness-based intervention thresholds applicable to patients with different combinations of clinical risk factors, which more closely matches the situation in clinical practice. Denosumab is cost-effective in patients with major osteoporotic fracture probabilities meeting or exceeding approximately 20% who are unable to take, comply with or tolerate generic alendronate.

Citing Articles

Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021.

Corrao G, Biffi A, Porcu G, Ronco R, Adami G, Alvaro R Front Endocrinol (Lausanne). 2023; 14:1137671.

PMID: 37143730 PMC: 10151776. DOI: 10.3389/fendo.2023.1137671.

Integrating economic considerations into cutpoint selection may help align clinical decision support toward value-based healthcare.

Parsons R, Blythe R, Cramb S, McPhail S J Am Med Inform Assoc. 2023; 30(6):1103-1113.

PMID: 36970849 PMC: 10198528. DOI: 10.1093/jamia/ocad042.

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea.

Kang J, Choi L, Johnson B, Yang H J Bone Metab. 2022; 29(2):83-92.

PMID: 35718925 PMC: 9208907. DOI: 10.11005/jbm.2022.29.2.83.

Acute kidney injury after hip fracture surgery in patients over 80 years of age.

Agar A, Gulabi D, Sahin A, Gunes O, Hancerli C, Kilic B Arch Orthop Trauma Surg. 2021; 142(9):2245-2252.

PMID: 34056678 DOI: 10.1007/s00402-021-03969-y.

Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal.

Azharuddin M, Adil M, Khan R, Ghosh P, Kapur P, Sharma M Osteoporos Sarcopenia. 2020; 6(2):39-52.

PMID: 32715093 PMC: 7374246. DOI: 10.1016/j.afos.2020.05.006.

References

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2001; 39(12):1383-9. DOI: 10.1093/rheumatology/39.12.1383. View

Kanis J, Johansson H, Oden A, McCloskey E . Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009; 44(6):1049-54. DOI: 10.1016/j.bone.2009.02.014. View

Kurth A, Pfeilschifter J . [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006]. Orthopade. 2007; 36(7):683-90. DOI: 10.1007/s00132-007-1106-3. View

. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011; 154(5):356-64. DOI: 10.7326/0003-4819-154-5-201103010-00307. View

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View

Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S . Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop. 2008; 79(2):269-80. DOI: 10.1080/17453670710015094. View

SINGER B, McLauchlan G, Robinson C, Christie J . Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br. 1998; 80(2):243-8. DOI: 10.1302/0301-620x.80b2.7762. View

Freemantle N, Satram-Hoang S, Tang E, Kaur P, Macarios D, Siddhanti S . Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2011; 23(1):317-26. PMC: 3249211. DOI: 10.1007/s00198-011-1780-1. View

Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E . The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int. 2009; 21(3):495-505. DOI: 10.1007/s00198-009-0989-8. View

10.

Kanis J, Hans D, Cooper C, Baim S, Bilezikian J, Binkley N . Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011; 22(9):2395-411. DOI: 10.1007/s00198-011-1713-z. View

11.

McCloskey E, Johansson H, Oden A, Austin M, Siris E, Wang A . Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012; 27(7):1480-6. DOI: 10.1002/jbmr.1606. View

12.

Delmas P, Genant H, Crans G, Stock J, Wong M, Siris E . Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003; 33(4):522-32. DOI: 10.1016/s8756-3282(03)00241-2. View

13.

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385-97. PMC: 2267485. DOI: 10.1007/s00198-007-0543-5. View

14.

Dolan P . Modeling valuations for EuroQol health states. Med Care. 1997; 35(11):1095-108. DOI: 10.1097/00005650-199711000-00002. View

15.

Kanis J, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby A . The components of excess mortality after hip fracture. Bone. 2003; 32(5):468-73. DOI: 10.1016/s8756-3282(03)00061-9. View

16.

Borgstrom F, Jonsson B, Strom O, Kanis J . An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int. 2006; 17(12):1781-93. DOI: 10.1007/s00198-006-0193-z. View

17.

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View

18.

Klotzbuecher C, Ross P, Landsman P, Abbott 3rd T, Berger M . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4):721-39. DOI: 10.1359/jbmr.2000.15.4.721. View

19.

Kind P, Dolan P, Gudex C, Williams A . Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998; 316(7133):736-41. PMC: 28477. DOI: 10.1136/bmj.316.7133.736. View

20.

Kanis J, Reginster J, Kaufman J, Ringe J, Adachi J, Hiligsmann M . A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2011; 23(1):213-21. PMC: 3249199. DOI: 10.1007/s00198-011-1796-6. View